+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 518 Pages
  • July 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5645026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 29, 12, 1, 76, 42 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 8 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Cystic Fibrosis - Overview
  • Cystic Fibrosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cystic Fibrosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cystic Fibrosis - Companies Involved in Therapeutics Development
  • Cystic Fibrosis - Drug Profiles
  • (ammonium chloride + citric acid + sodium citrate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • (elexacaftor + ivacaftor + tezacaftor) + ivacaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • (ethylenediaminetetraacetic acid + sodium nitrite) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • (ivacaftor + lumacaftor) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • (ivacaftor + tezacaftor + bamocaftor potassium) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • (ivacaftor + tezacaftor) + ivacaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • 4D-710 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ABBV-191 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ABO-401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ACF-516 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ADDITIONAL SMALL MOLECULES 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • AGL-503 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • alidornase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • alpha-1 proteinase inhibitor (human) second generation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ANT-3273 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • APPA-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ARCT-032 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ARO-ENaC2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ARV-1907 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ascorbic acid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • AT-010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • AvR-2V10 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • BBP-321 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BFP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BFP-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • BI-1323495 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • BI-3720931 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • BIOC-51 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • BOS-857 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • BP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • BrB-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • brensocatib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • brevenal - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • BX-004 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Calcaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • CAT-5571 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • CB-280 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • CF-370 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • CGT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • CHF-6333 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • CMTX-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • colistimethate sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • CSA-13 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • cysteamine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • dirocaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • dornase alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drug for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drug to Inhibit SLPI for Asthma and Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drugs for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drugs to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Drugs to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • EBX-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ECP-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • EG-i08 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ELX-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ensifentrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ETD-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ETD-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ETX-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • EVXB-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • fenretinide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • FTX-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • fusidic acid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • galicaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Gene Therapy for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Gene Therapy for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy for Cystic Fibrosis and Retinitis Pigmentosa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • heparin sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • HY-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ICL4 Additional Candidates - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ivacaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • KB-407 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • KIT-2014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • lefamulin acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • LMS-611 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • lonodelestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • MG-277 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • MRT-5005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Mul-1867 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • murepavadin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • N-115 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • nadolol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • nafamostat mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • NAS-415 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • navocaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • NBD1 Additional Candidates - Drug Profile
  • Product Description
  • Mechanism Of Action
  • nesolicaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • niclosamide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • NU-8 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • OligoG - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Oligonucleotide to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Oligonucleotide to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Oligonucleotides for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Oligonucleotides to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Optate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • ORP-100S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • ORP-110 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • OTP-602 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • P-2114 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • P-2176 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Pemziviptadil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • PLG-0301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • posenacaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • pravibismane - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis, Hospital Acquired Pneumonia and Diabetic Foot Infection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • PTINC-733 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RBR-042 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Recombinant Enzyme to Inhibit DNA for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • renzapride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RP-557 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RSBT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RTX-0001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • RVT-801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • S-1226 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • S-1229 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Sanguinate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SBI-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SCB-203 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • seliciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SHP-111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SHP-636 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SION-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SION-638 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules for Respiratory Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules to Block SCNN1 for Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Small Molecules to Inhibit Penicillin Binding Protein for Gram-Negative Bacterial Infections and Cystic Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SNSP-113 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • sodium calcium edetate + tobramycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • sodium nitrite - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SOL-512 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SPIRO-2101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SPIRO-2102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SPIRO-2110 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SPL-16 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SPL-232 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SPL-24N - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SPL-5A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SPL-5B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SPL-8423 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SRI-41315 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • SYD-0073 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • SYGN-303 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • TA-270 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • TAVT-135 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • teicoplanin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • thymalfasin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • thymalfasin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • TMD1 Candidates - Drug Profile
  • Product Description
  • Mechanism Of Action
  • tobramycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • tobramycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • tobramycin + triclosan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • trimethylangelicin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • VS-009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • VX-121 + deutivacaftor + tezacaftor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • VX-551 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • VXc-0522 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • VXc-522 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • XF-70 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • YPT-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • zelpultide alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Cystic Fibrosis - Dormant Projects
  • Cystic Fibrosis - Discontinued Products
  • Cystic Fibrosis - Product Development Milestones
  • Featured News & Press Releases
  • Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound
  • Jul 07, 2022: Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for public reimbursement of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children With cystic fibrosis ages 6 and older
  • Jun 11, 2022: Vertex to present data demonstrating significant benefits of long-term and early treatment With CFTR modulators at the European Cystic Fibrosis Conference
  • May 18, 2022: Recode therapeutics presents new preclinical data from mRNA-based program for cystic fibrosis at the ATS 2022 International Conference
  • Apr 21, 2022: Health Canada approves Vertex’s Trikafta for cystic fibrosis in children
  • Apr 18, 2022: ContraFect announces multiple presentations of new data demonstrating the potential of its Direct Lytic Agent CF-370 to address antimicrobial resistance at the 32nd Annual ECCMID Meeting
  • Apr 12, 2022: Entrinsic Bioscience steps closer to amino acid formulation as therapy for cystic fibrosis
  • Apr 11, 2022: Nabriva Therapeutics announces first patient enrolled in phase 1 trial of XENLETA (lefamulin) in adult patients with cystic fibrosis
  • Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine
  • Mar 29, 2022: Eloxx Pharmaceuticals announces therapeutic development Award from Cystic Fibrosis Foundation
  • Mar 26, 2022: Vertex announces reimbursement agreement in Australia for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients With cystic fibrosis ages 12 years and older with at least one F508del mutation in the CFTR gene
  • Mar 25, 2022: Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H Mutation in the CFTR Gene
  • Jan 12, 2022: EC approves Vertex’s combination therapy for cystic fibrosis in children
  • Jan 05, 2022: SpliSense announces FDA and EMA grant Orphan Drug Designation to SPL84-23-1 for the treatment of cystic fibrosis
  • Jan 05, 2022: Peptilogics receives award from the Cystic Fibrosis Foundation to investigate PLG0301 as potential dual-acting treatments for lung infections associated with cystic fibrosis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Cystic Fibrosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Target, 2022 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Cystic Fibrosis - Dormant Projects, 2022
  • Cystic Fibrosis - Discontinued Products, 2022
  • Cystic Fibrosis - Discontinued Products, 2022 (Contd..1)

List of Figures
  • Number of Products under Development for Cystic Fibrosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 4D Molecular Therapeutics Inc
  • AbbVie Inc
  • Abeona Therapeutics Inc
  • Aceragen Inc
  • Aeon Respire Inc
  • Agile Sciences Inc
  • AiCuris Anti-infective Cures AG
  • Airbase Breathing Co LLC
  • Airway Therapeutics Inc
  • AlgiPharma AS
  • Antabio SAS
  • Arch Biopartners Inc
  • Arcturus Therapeutics Holdings Inc
  • Armata Pharmaceuticals Inc
  • Arrevus Inc
  • Arrowhead Pharmaceuticals Inc
  • Astria Therapeutics Inc
  • Atlantic Healthcare Plc
  • Avidin Biotechnology Ltd
  • Biofilm Pharma
  • Biolytx Pharmaceuticals Corp
  • BiomX Inc
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Branca Bunus Ltd
  • Breathe Easy Therapeutics Ltd
  • BridgeBio Pharma Inc
  • Calista Therapeutics Inc
  • Calithera Biosciences Inc
  • Carbon Biosciences Inc
  • Chiesi Farmaceutici SpA
  • Cilian AG
  • Clarametyx Biosciences Inc
  • ContraFect Corp
  • Copernicus Therapeutics Inc
  • CRISPR Therapeutics AG
  • CSA Biotechnologies LLC
  • Cyclacel Pharmaceuticals Inc
  • Cyclenium Pharma Inc
  • Destiny Pharma Plc
  • DiscoveryBiomed Inc
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • EmphyCorp Inc
  • enGene Inc
  • Enterprise Therapeutics Ltd
  • Entrinsic Bioscience Inc
  • Evaxion Biotech ApS
  • Evotec SE
  • F. Hoffmann-La Roche Ltd
  • Feldan Therapeutics Inc
  • Felix Biotechnology Inc
  • Helperby Therapeutics Group Ltd
  • Hunterian Medicine LLC
  • Icagen Inc
  • Insmed Inc
  • Invion Ltd
  • Kamada Pharmaceuticals
  • Kither Biotech Srl
  • Krystal Biotech Inc
  • Lakewood-Amedex Inc
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc
  • Loxegen Pty Ltd
  • MannKind Corp
  • Mariposa Health Ltd
  • Microbion Corp
  • Mucokinetica Ltd
  • Nabriva Therapeutics Plc
  • Nanogenics Ltd
  • Neupharma Srl
  • New Amsterdam Sciences Inc
  • Novabiotics Ltd
  • Omnispirant Ltd
  • Orphomed Inc
  • OrPro Therapeutics Inc
  • Oryn Therapeutics
  • Parion Sciences Inc
  • Peptilogics Inc
  • Peter Biotherapeutics Inc
  • Pharmaero ApS
  • PhaseBio Pharmaceuticals Inc
  • Progenra Inc
  • Prolong Pharmaceuticals LLC
  • PureIMS BV
  • Pylum Biosciences Inc
  • RAGE Biotech Pty Ltd
  • Rare Partners Srl
  • Reata Pharmaceuticals Inc
  • Recode Therapeutics Inc
  • Renovion Inc
  • Respirion Pharmaceuticals Pty Ltd
  • Riptide Bioscience Inc
  • RS BioTherapeutics Inc
  • Saliogen Therapeutics Inc
  • San Rocco Therapeutics LLC
  • Sanofi
  • Santhera Pharmaceuticals Holding AG
  • Sarcomed AB
  • SciBac Inc
  • SciClone Pharmaceuticals Holdings Ltd
  • Shape Therapeutics Inc
  • Silurian Pharmaceuticals Inc
  • Sionna Therapeutics Inc
  • SOLA Biosciences LLC
  • SolAeroMed Inc
  • Specific Biologics Inc
  • Spexis AG
  • Spirovant Sciences Inc
  • SpliSense Ltd
  • Synedgen Inc
  • Synovo GmbH
  • Synspira Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Tavanta Therapeutics Inc
  • TGV-Inhalonix Inc
  • Therapeutic Systems Research Laboratories Inc
  • Thirty Respiratory Ltd
  • Translate Bio Inc
  • Vast Therapeutics Inc
  • Vectura Group Plc
  • Vera Therapeutics Inc
  • Verona Pharma Plc
  • Vertex Pharmaceuticals Inc
  • VGSK Technologies Inc
  • Vironika LLC
  • Yumanity Therapeutics Inc
  • Zambon Co SpA
  • Zata Pharmaceuticals Inc